Intl Land Allianceの空売り状況は、投資家がIntl Land Allianceの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Intl Land Alliance (OTC:ILAL) 株価情報, 空売り情報

International Land Alliance Inc is a residential land development company with target properties located in the Baja California, Norte region of Mexico. Its activities include purchasing properties, obtaining zoning and other entitlements required to subdivide the properties into residential and commercial building plots, securing financing for the purchase of the plots, improving the property's infrastructure and amenities, and selling the plots to homebuyers, retirees, investors, and commercial developers. The Company's real estate portfolio includes Oasis Park Resort, Valle Divino in Ensenada, Plaza Bajamar Resort which is part of Bajamar Oceanfront hotel and Golf Resort, Emerald Grove Estates in Southern California, and lastly Rancho Costa Verde, on Baja California's east coast.

INTERNATIONAL LAND ALLICE by International Land Alliance Inc.

International Land Alliance Inc

Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) reported quarterly earnings of $1.22 per share which missed the analyst consensus estimate of $1.24 by 1.61 percent. This is a 27.08 percent increase over earnings of $0.96 per share from the same period last year. The company reported quarterly sales of $453.75 million which missed the analyst consensus estimate of $458.42 million by 1.02 percent. This is a 16.81 percent increase over sales of $388.46 million the same period last year.

Earnings

Earnings Misses

News

BOOT

Boot Barn Holdings Q4 GAAP EPS $1.22 Misses $1.24 Estimate, Sales $453.75M Miss $458.42M Estimate

Stock Split

AGMH

AGM Group Holdings Announces 50 For 1 Share Consolidation

Bank of America Securities analyst Curtis Nagle rerated internet and e-commerce stocks RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) and Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) on Wednesday.
Nagle downgraded RH, or Restoration Hardware, to Underperform and <a href="https://www.benzinga.com/quote/RH/analyst-ratings" target="_blank" rel="noreferrer noopener">raised the price target</a> from $144 to $172.
Nagle rerated after the company&#8217;s fourth-quarter 2024 earnings call that also coincided with Liberation Day, primarily on significant margin risk from tariffs and a weaker demand outlook.
Also Read: <a href="https://www.benzinga.com/general/social-media/25/04/44747892/amazon-wayfair-pinterest-win-analyst-backing-due-to-tariff-pause-supply-chain-relief-discretionary-spend-recovery" target="_blank" rel="noreferrer noopener">Amazon, Wayfair, Pinterest Win Analyst Backing Due To Tariff Pause, Supply Chain Relief, Discretionary Spend Recovery</a>
These reduced tariffs remove a substantial overhang to RH sentiment and margins. However, the analyst remained cautious on demand trends throughout the year and noted continued risk to fiscal year guidance, particularly with a weaker outlook for housing and consumer discretionary spending that could offset RH share gains versus peers. Street estimates are at the low end of 2025 guidance but assume a sharp acceleration in 2-year revenue growth trends and over 100bps of gross margin expansion in the second half.
Prior to the US lowering tariff rates across the board, Nagle&#8217;s analysis indicated that full tariffs would significantly weigh on RH&#8217;s operating margins. Even when assuming substantial mitigation efforts and SG&amp;A cuts, the analyst noted tariff costs would be far more manageable.
Despite removing significant tariff headwinds, several key factors kept the analyst cautious on RH. The company reported that demand growth through April 4 (before tariff impacts) plateaued at 17%, while BAC card data &amp; data on luxury home volumes by the National Association of Realtors suggest decelerating quarter-to-date trends for the industry. 
The guidance does not incorporate tariff costs, which could still weigh on second-half gross margins. While RH expects positive free cash flow, most of this will be driven by stockpiled inventory, RH&#8217;s high net leverage at 5 times, and cash interest expense.
Despite several added headwinds, the stock is now near its five-year average of 19 times and effectively back at its pre-fourth-quarter levels. Still, an improved tariff outlook removes a significant overhang on the stock, which Nagle noted will be reflected in the stock&#8217;s multiple.
Nagle raised his RH fiscal 2025 revenue and EBIT by 1.5% and 7.6% to $3.51 billion and $463 million from $3.45 billion and $430 million to reflect a slightly improved tariff outlook. His fiscal 2025 revenue and EBIT estimates are still 0.3% and 5.2% below the Street. For fiscal 2026, he raised his revenue and EBIT by 2.1% and 2.5% to $3.86 billion and $564 million from $3.78 billion and $550 million.
Nagle maintained Wayfair with a Neutral and <a target="_blank" href="https://www.benzinga.com/quote/W/analyst-ratings" rel="noreferrer noopener">raised the price target</a> from&nbsp;$36&nbsp;to&nbsp;$43.
With China tariffs now lowered to 30% (from 145%), Nagle noted tariff-related costs more manageable for Wayfair, particularly since Wayfair likely has the highest sourcing exposure to China within his Online furnishings coverage.
The price target boost reflects higher sector valuation and a de-escalation in tariff rhetoric.
Price Actions: RH stock is down 3.18% at $218.50 at last check Wednesday. W is down 0.25%.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45416148/pony-ai-shares-rise-after-report-of-confidential-hong-kong-ipo-to-fund-robotaxi-expansion" target="_blank" rel="noreferrer noopener">Robotaxi Service Pony AI Stock Falls Despite IPO Buzz &#8211; Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Price Target

Reiteration

Analyst Ratings

Trading Ideas

RH Faces Margin Pressure Despite Tariff Relief, Analyst Flags Weaker Housing Demand Ahead

Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) reported quarterly sales of $141.20 million which missed the analyst consensus estimate of $159.37 million by 11.40 percent. This is a 159.80 percent increase over sales of $54.35 million the same period last year.

IREN

Iris Energy Q3 Sales $141.20M Miss $159.37M Estimate

WIIM

SPIR

Spire Global shares are trading higher after the company reported a Q1 revenue beat and announced it won a 10-year U.S. Space Force contract.

Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 82.54 percent increase over losses of $(3.55) per share from the same period last year.

CTNM

Contineum Therapeutics Q1 EPS $(0.62) Misses $(0.58) Estimate

Buybacks

Boot Barn Authorized $200M Repurchase Program

Nextracker Acquires Bentek Corporation For $78M In Cash Including Future Contingent Earnout Consideration

Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.31 by 16.13 percent. This is a 12.5 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $151.41 million which beat the analyst consensus estimate of $146.30 million by 3.49 percent. This is a 12.86 percent increase over sales of $134.16 million the same period last year.

Earnings Beats

NVGS

Navigator Holdings Q1 Adj. EPS $0.36 Beats $0.31 Estimate, Sales $151.41M Beat $146.30M Estimate

Fidelis Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIHL#NYSE">FIHL</a>) reported quarterly losses of $(0.41) per share which met the analyst consensus estimate. This is a 155.41 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $658.40 million which missed the analyst consensus estimate of $927.63 million by 29.02 percent. This is a 26.62 percent increase over sales of $520.00 million the same period last year.

FIHL

Fidelis Insurance Hldgs Q1 Adj. EPS $(0.41), Inline, Sales $658.40M Miss $927.63M Estimate

Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) has outperformed the market over the past 10 years by 2.33% on an annualized basis producing an average annual return of 13.01%. Currently, Encompass Health has a market capitalization of $12.03 billion. 
Buying $1000 In EHC: If an investor had bought $1000 of EHC stock 10 years ago, it would be worth $3,395.37 today based on a price of $119.27 for EHC at the time of writing.
<h3>Encompass Health's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747253717_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Encompass Health 10 Years Ago Would Be Worth This Much Today

Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) affirms FY2025 sales outlook from $460.00 million-$480.00 million to $460.00 million-$480.00 million vs $482.80 million estimate.

Guidance

Oncology Institute Affirms FY2025 Sales Guidance of $460.00M-$480.00M vs $482.80M Est

RCAT

Red Cat Holdings shares are trading lower after the company reported worse-than-expected Q1 financial results.

<ul>
<li>Most Studies Meeting the Literature Review Criteria Found That a Higher Glucocorticoid Dose was Statistically Significantly Associated with Adverse Clinical Outcomes</li>
<li>Findings Presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research Annual Meeting</li>
</ul>

Biotech

Events

General

NBIX

Neurocrine Biosciences Presents Study Showing Relationship Between Higher Glucocorticoid Dose And Adverse Clinical Outcomes

Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) reported quarterly losses of $(0.48) per share. This is a 284.62 percent decrease over earnings of $0.26 per share from the same period last year. The company reported $26.89 million in sales this quarter. This is a 21.39 percent decrease over sales of $34.22 million the same period last year.

NSYS

Nortech Systems Q1 EPS $(0.48) Down From $0.26 YoY, Sales $26.89M Down From $34.22M YoY

IBTA

Ibotta shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance with its midpoint above estimates.

Incannex Healthcare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares surged 876% to 83 cents on Wednesday after the company <a href="https://www.benzinga.com/pressreleases/25/05/g45403793/incannex-healthcare-inc-provides-clinical-program-update-on-ihl-42x-an-oral-once-daily-treatment-f">announced</a> the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA trial for IHL-42X, an investigational oral treatment for obstructive sleep apnea (OSA).
What To Know: The milestone marks a key step as the company prepares for an end-of-Phase 2 FDA meeting and anticipates top-line results in July.
IHL-42X <a href="https://www.benzinga.com/pressreleases/25/05/g45403793/incannex-healthcare-inc-provides-clinical-program-update-on-ihl-42x-an-oral-once-daily-treatment-f">targets</a> underlying mechanisms of OSA, intermittent hypoxia and hypercapnia, and could offer a pharmacological alternative to CPAP devices.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/05/45418609/fda-approves-mercks-kidney-cancer-drug-for-rare-type-of-neuroendocrine-tumors">FDA Approves Merck&#8217;s Kidney Cancer Drug For Rare Type Of Neuroendocrine Tumors</a>
Prior trials showed a 51% reduction in Apnea-Hypopnea Index at the lowest dose and significant improvements in oxygen desaturation burden, a key predictor of cardiovascular risk.
Phase 3 of the trial will enroll 440 U.S. patients, reflecting strong local interest. Incannex is also exploring commercial partnerships for IHL-42X. 
CEO Joel Latham said the third quarter of 2025 will be pivotal, with regulatory and clinical milestones positioning IHL-42X as a first-in-class oral OSA therapy for a broad patient population.
<h1 class="wp-block-heading">How To Buy IXHL Stock</h1>
By now you're likely curious about how to participate in the market for Incannex Healthcare — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Incannex Healthcare, which is trading at 83 cents as of publication on Wednesday, $100 would buy you 120.48 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, IXHL has a 52-week high of $3.55 and a 52-week low of eight cents.
Read Also: 
 • <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45417105/tesla-stock-continues-to-climb-whats-going-on">Tesla Stock Continues To Climb: What&#8217;s Going On?</a>

Photo: Shutterstock

Health Care

Movers

IXHL

Incannex Healthcare (IXHL) Stock Soars Over 800%: What's Going On?

The Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) reported quarterly losses of $(0.21) per share. This is a 4.55 percent increase over losses of $(0.22) per share from the same period last year. The company reported $104.41 million in sales this quarter. This is a 10.29 percent increase over sales of $94.67 million the same period last year.

The Oncology Institute Q1 GAAP EPS $(0.21) Up From $(0.22) YoY, Sales $104.41M Up From $94.67M YoY

Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) reported quarterly losses of $(1.15) per share which beat the analyst consensus estimate of $(3.02) by 61.92 percent. This is a 96.78 percent increase over losses of $(35.75) per share from the same period last year. The company reported quarterly sales of $6.50 million which beat the analyst consensus estimate of $6.23 million by 4.28 percent. This is a 25.88 percent decrease over sales of $8.77 million the same period last year.

Comments

Intl Land Alliance

空売り

Intl Land Alliance (OTC:ILAL) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル